Cancer cell genotype associated tumor immune microenvironment exhibits differential response to therapeutic STING pathway activation in high-grade serous ovarian cancer.

Noor ShakfaDeyang LiGwenaelle ConseilElizabeth D LightbodyJuliette Wilson-SanchezAli HamadeStephen ChenardNatasha A JawaBrian J LaightAfrakoma Afriyie-AsanteKathrin TyryshkinMartin KoebelMadhuri Koti

Published in: Journal for immunotherapy of cancer (2023)

This study reveals the importance of considering the influence of cancer cell intrinsic genetic alterations on the TIME for therapeutic selection. We establish the rationale for the optimal incorporation of interferon activating therapies as a novel combination strategy in PTEN-deficient HGSC.

Keyphrases

high grade
low grade
stem cells
signaling pathway
dendritic cells
clinical trial
gene expression
dna methylation